377 related articles for article (PubMed ID: 32664210)
1. Bi- and Tri-Specific T Cell Engager-Armed Oncolytic Viruses: Next-Generation Cancer Immunotherapy.
Guo ZS; Lotze MT; Zhu Z; Storkus WJ; Song XT
Biomedicines; 2020 Jul; 8(7):. PubMed ID: 32664210
[TBL] [Abstract][Full Text] [Related]
2. Revolutionizing cancer treatment: the power of bi- and tri-specific T-cell engagers in oncolytic virotherapy.
Zarezadeh Mehrabadi A; Tat M; Ghorbani Alvanegh A; Roozbahani F; Esmaeili Gouvarchin Ghaleh H
Front Immunol; 2024; 15():1343378. PubMed ID: 38464532
[TBL] [Abstract][Full Text] [Related]
3. Solid Tumor Immunotherapy with T Cell Engager-Armed Oncolytic Viruses.
Scott EM; Duffy MR; Freedman JD; Fisher KD; Seymour LW
Macromol Biosci; 2018 Jan; 18(1):. PubMed ID: 28902983
[TBL] [Abstract][Full Text] [Related]
4. Oncolytic viruses encoding bispecific T cell engagers: a blueprint for emerging immunovirotherapies.
Heidbuechel JPW; Engeland CE
J Hematol Oncol; 2021 Apr; 14(1):63. PubMed ID: 33863363
[TBL] [Abstract][Full Text] [Related]
5. Improving CART-Cell Therapy of Solid Tumors with Oncolytic Virus-Driven Production of a Bispecific T-cell Engager.
Wing A; Fajardo CA; Posey AD; Shaw C; Da T; Young RM; Alemany R; June CH; Guedan S
Cancer Immunol Res; 2018 May; 6(5):605-616. PubMed ID: 29588319
[TBL] [Abstract][Full Text] [Related]
6. Nanobody-based trispecific T cell engager (Nb-TriTE) enhances therapeutic efficacy by overcoming tumor-mediated immunosuppression.
Ding Z; Sun S; Wang X; Yang X; Shi W; Huang X; Xie S; Mo F; Hou X; Liu A; Jiang X; Tang Z; Lu X
J Hematol Oncol; 2023 Nov; 16(1):115. PubMed ID: 38031188
[TBL] [Abstract][Full Text] [Related]
7. Bi- and tri-valent T cell engagers deplete tumour-associated macrophages in cancer patient samples.
Scott EM; Jacobus EJ; Lyons B; Frost S; Freedman JD; Dyer A; Khalique H; Taverner WK; Carr A; Champion BR; Fisher KD; Seymour LW; Duffy MR
J Immunother Cancer; 2019 Nov; 7(1):320. PubMed ID: 31753017
[TBL] [Abstract][Full Text] [Related]
8. Bispecific T cell engagers and their synergistic tumor immunotherapy with oncolytic viruses.
Huang Q; Cai WQ; Han ZW; Wang MY; Zhou Y; Cheng JT; Zhang Y; Wang YY; Xin Q; Wang XW; Peng XC; Xiang Y; Fang SX; Ma ZW; Xin HY; Cui SZ; Xin HW
Am J Cancer Res; 2021; 11(6):2430-2455. PubMed ID: 34249409
[TBL] [Abstract][Full Text] [Related]
9. Oncolytic herpesvirus expressing PD-L1 BiTE for cancer therapy: exploiting tumor immune suppression as an opportunity for targeted immunotherapy.
Khalique H; Baugh R; Dyer A; Scott EM; Frost S; Larkin S; Lei-Rossmann J; Seymour LW
J Immunother Cancer; 2021 Mar; 9(4):. PubMed ID: 33820820
[TBL] [Abstract][Full Text] [Related]
10. [Preparation of CD33 targeted bispecific- and trispecific-T cell engagers and their cytotoxicity on leukemia cells].
Zhang T; Chen ML; Liu XY; He HZ; Xu YX; Tian Z; Xing HY; Tang KJ; Rao Q; Wang M; Wang JX
Zhonghua Xue Ye Xue Za Zhi; 2022 May; 43(5):376-382. PubMed ID: 35680594
[No Abstract] [Full Text] [Related]
11. Targeting the tumor stroma with an oncolytic adenovirus secreting a fibroblast activation protein-targeted bispecific T-cell engager.
de Sostoa J; Fajardo CA; Moreno R; Ramos MD; Farrera-Sal M; Alemany R
J Immunother Cancer; 2019 Jan; 7(1):19. PubMed ID: 30683154
[TBL] [Abstract][Full Text] [Related]
12. Oncolytic Adenovirus Armed with BiTE, Cytokine, and Checkpoint Inhibitor Enables CAR T Cells to Control the Growth of Heterogeneous Tumors.
Porter CE; Rosewell Shaw A; Jung Y; Yip T; Castro PD; Sandulache VC; Sikora A; Gottschalk S; Ittman MM; Brenner MK; Suzuki M
Mol Ther; 2020 May; 28(5):1251-1262. PubMed ID: 32145203
[TBL] [Abstract][Full Text] [Related]
13. Activation of distinct antiviral T-cell immunity: A comparison of bi- and trispecific T-cell engager antibodies with a chimeric antigen receptor targeting HBV envelope proteins.
Debelec-Butuner B; Quitt O; Schreiber S; Momburg F; Wisskirchen K; Protzer U
Front Immunol; 2022; 13():1029214. PubMed ID: 36405686
[TBL] [Abstract][Full Text] [Related]
14. Claudin18.2 bispecific T cell engager armed oncolytic virus enhances antitumor effects against pancreatic cancer.
Liu S; Li F; Deng L; Ma Q; Lu W; Zhao Z; Liu H; Zhou Y; Hu M; Wang H; Yan Y; Zhao M; Zhang H; Du M
Mol Ther Oncolytics; 2023 Sep; 30():275-285. PubMed ID: 37701851
[TBL] [Abstract][Full Text] [Related]
15. IL-21 arming potentiates the anti-tumor activity of an oncolytic vaccinia virus in monotherapy and combination therapy.
Chen T; Ding X; Liao Q; Gao N; Chen Y; Zhao C; Zhang X; Xu J
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33504576
[TBL] [Abstract][Full Text] [Related]
16. Combining Oncolytic Viruses With Cancer Immunotherapy: Establishing a New Generation of Cancer Treatment.
Shi T; Song X; Wang Y; Liu F; Wei J
Front Immunol; 2020; 11():683. PubMed ID: 32411132
[TBL] [Abstract][Full Text] [Related]
17. Oncolytic adenovirus expressing bispecific antibody targets T-cell cytotoxicity in cancer biopsies.
Freedman JD; Hagel J; Scott EM; Psallidas I; Gupta A; Spiers L; Miller P; Kanellakis N; Ashfield R; Fisher KD; Duffy MR; Seymour LW
EMBO Mol Med; 2017 Aug; 9(8):1067-1087. PubMed ID: 28634161
[TBL] [Abstract][Full Text] [Related]
18. Oncolytic Adenoviral Delivery of an EGFR-Targeting T-cell Engager Improves Antitumor Efficacy.
Fajardo CA; Guedan S; Rojas LA; Moreno R; Arias-Badia M; de Sostoa J; June CH; Alemany R
Cancer Res; 2017 Apr; 77(8):2052-2063. PubMed ID: 28143835
[TBL] [Abstract][Full Text] [Related]
19. Immunovirotherapy: The role of antibody based therapeutics combination with oncolytic viruses.
Jafari M; Kadkhodazadeh M; Shapourabadi MB; Goradel NH; Shokrgozar MA; Arashkia A; Abdoli S; Sharifzadeh Z
Front Immunol; 2022; 13():1012806. PubMed ID: 36311790
[TBL] [Abstract][Full Text] [Related]
20. An oncolytic vaccinia virus armed with anti-human-PD-1 antibody and anti-human-4-1BB antibody double genes for cancer-targeted therapy.
Shi Z; Liu B; Huang C; Xie W; Cen Y; Chen L; Liang M
Biochem Biophys Res Commun; 2021 Jun; 559():176-182. PubMed ID: 33945995
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]